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Doctors treating patients who have had an acute 
ischaemic stroke must feel the need for speed more 
feverishly than a racing driver. Stroke does not hurt. 
There is none of the pain that might be registered on 
the face of a patient with acute myocardial infarction or 
the visceral sight of blood in the case of trauma to evoke 
a sense of immediacy. Yet stroke is exactly like acute 
myocardial infarction and acute trauma in the need for 
very fast treatment.
In The Lancet, Jonathan Emberson and colleagues 
present a pre-planned analysis of pooled individual 
data for 6756 patients from all the major trials 
of thrombolysis for treatment of stroke.1 Overall, 
thrombolysis with alteplase unequivocally resulted in 
more patients with an excellent neurological outcome 
at 3–6 months compared with control. This overall 
outcome included an increase in the number of early 
fatal intracerebral haemorrhages, but the result is 
deﬁ nitive. Thrombolysis is an eﬀ ective treatment, 
especially when given fast.
Time is the major modiﬁ er of the eﬀ ect of treatment: 
faster treatment results in a much greater treatment 
eﬀ ect.1 In Emberson and colleagues’ analysis, treatment 
within 3 h resulted in a good outcome for about 33% of 
patients who took alteplase compared with 23% who 
took control (odds ratio [OR] 1·75, 95% CI 1·35–2·27); 
delay of more than 3·0 h but less than 4·5 h resulted 
in good outcome for 35% versus 30% (OR 1·26, 
95% CI 1·05–1·51); and delay of more than 4·5 h resulted 
in good outcome for 33% versus 31% (OR 1·15, 
95% CI 0·95–1·40). Age and stroke severity did not 
modify the eﬀ ect of treatment; both young and old 
patients, and those who had both mild and severe 
strokes, beneﬁ tted from thrombolysis.
Audits2,3 show that patients with ischaemic stroke are 
oﬀ ered thrombolysis too rarely or, if they are oﬀ ered it, 
too slowly. Quick treatment requires eﬃ  cient processes 
and a team approach. Pre-hospital systems to identify 
patients and bring them to the appropriate hospitals, 
emergency department swarming, rapid simple 
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changes that are needed to promote evidence-based 
research. One of the objectives of the EBR Network is that 
all doctoral students, supervisors, and senior researchers 
should learn the methodology of systematic reviews and 
use these research syntheses to anchor more eﬀ ectively 
questions for additional primary research. We wish the 
new EBR Network well and urge the research community 
to support it. 
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imaging, and use of telemedicine must be harnessed to 
reduce times to treatment. Strategies to do so will vary 
by region but it is simply unacceptable not to achieve 
very fast treatment times. In Berlin, Germany, the use of 
a CT scanner in the ambulance and point-of-care blood 
testing combined with a telemedicine link has enabled 
patients to be given alteplase very quickly, even before 
they reach the hospital.4 In Helsinki, Finland, quick 
hospital-based treatment is possible with a median 
time from door to treatment of 20 min in one study.5 
However, in most of the world, patients are rarely 
treated that fast.
Emberson and colleagues show that the treatment 
beneﬁ t is similar for young and old patients, with no 
evidence to support the use of diﬀ erent approaches 
for patients of diﬀ erent ages. Clearly, older patients 
should be considered for thrombolysis. Furthermore, 
the beneﬁ t for patients with mild stroke is notable 
given the continuing discussion about whether or not 
to treat patients with mild stroke. The data render 
obsolete the European licensing label for alteplase—
which excludes patients older than 80 years and those 
with severe stroke. The ﬁ nding of a small beneﬁ t of 
treatment up to 4·5 h from onset makes the advice 
of the US Food and Drug Administration and Health 
Canada to not treat patients after 3 h from onset 
similarly outdated.
The question now is not whether we can extend the 
window for treatment. Rather, how do we get everyone 
treated faster and how do we dispel preconceived 
notions about not treating older patients or those with 
milder strokes? We must move from the proven science 
to policy and systems of care.
Benchmarks for treatment times should be revised, 
audited, and enforced. The widely adopted standard of 
60 min from door to needle is ﬁ ne if 95% of patients 
are treated within 60 min. It is not, however, an 
acceptable average or guide. A median of 30 min is a 
better target because it aﬀ ords an extra 30 min leeway, 
which still permits a 95th percentile of 60 min overall. 
Hospitals and teams that can achieve these targets, 
typically centres that treat many patients,6 can be 
accredited as acute stroke centres. Those that cannot 
should allow stroke care to be centralised to those 
centres that can.
Licensing bodies might consider changes. 
Accreditation bodies should update their targets 
and enact them as policy. Funding typically follows 
accreditation and this will be a crucial incentive for (and 
a means to) the achievement of fast treatment times. 
Further analyses of the trial data analysed by Emberson 
and colleagues will help us to understand the nuances 
of stroke, such as the eﬀ ects of CT scan appearance (as 
assessed by the ASPECTS score),7,8 blood pressure, blood 
glucose concentration,9,10 even why women have greater 
relative beneﬁ t than men.11 But the biology of stroke 
is clear and immutable: patients must be treated with 
extraordinary speed. Delayed treatment is the same as 
no treatment. We have to adapt our systems of care to 
the biology of the disease because we cannot adapt the 
biology to our systems. Drivers, start your engines.
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Intensive glucose treatment in patients with 
type 2 diabetes is associated with a reduction in 
microvascular complications, but the eﬀ ects on 
cardiovascular disease remain controversial.1–3 In the 
ACCORD trial,2 done in 10 251 patients with a mean 
age of 62·2 years at baseline and type 2 diabetes for 
at least 10 years, intensive glycaemic treatment was 
associated with an increased risk of cardiovascular and 
all-cause mortality. Post-hoc analyses showed that the 
increased risk occurred in patients who did not achieve 
concentrations of glycated haemoglobin A1C (HbA1c ) 
lower than 53 mmol/mol (7·0%),4 that the prevalence 
of neuropathy of the autonomic nervous system was 
similar in both groups,5 and that only 9·5% and 10·5% 
of deaths could be attributed to severe hypoglycaemia 
in the intensive and standard glycaemic therapy groups, 
respectively.6 Thus, severe hypoglycaemia does not 
explain the increased mortality and, therefore, this 
ﬁ nding could have been due to chance.7
In The Lancet, Hertzel Gerstein and colleagues8 
report a further post-hoc analysis of the ACCORD 
data that was done to investigate the eﬀ ects of 
intensive glucose lowering (target HbA1C concentration 
less than 42 mmol/mol [6·0%]) versus standard 
glucose lowering (target HbA1C concentration 
53–63 mmol/mol [7·0–7·9%]) with multiple antidiabetic 
drugs on composite outcomes of ischaemic heart 
disease. Intensive treatment, which patients received for 
a mean of 3·7 years followed by standard therapy for a 
further mean 1·2 years, was associated with reductions 
in non-fatal myocardial infarction (hazard ratio [HR] 
0·81, 95% CI 0·70–0·95), revascularisation (0·84, 
0·75–0·94), and unstable angina (0·81, 0·67–0·97), and 
a non-signiﬁ cant reduction in new-onset angina (0·76, 
0·55–1·06). In patients who received intensive therapy 
followed by standard therapy there was a non-signiﬁ cant 
increase in fatal myocardial infarction (1·68, 0·87–3·24). 
Adjustment for HbA1C concentration before the 
transition from intensive to standard treatment 
attenuated all hazard ratios to neutral, except for that 
for fatal myocardial infarction (1·87, 0·82–4·26), which 
favoured standard therapy, although not signiﬁ cantly.
Four major trials have tested the eﬀ ects of intensive 
versus standard glycaemic control on major cardiovascular 
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